Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:AbbVie
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
Mark Enyedy
|
| gptkbp:collaboratedWith |
gptkb:Takeda
gptkb:Eli_Lilly_and_Company gptkb:Sanofi gptkb:Amgen gptkb:Novartis gptkb:Roche |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
targeted cancer therapeutics
|
| gptkbp:focus |
antibody-drug conjugates
|
| gptkbp:focusesOn |
gptkb:cancer
hematologic malignancies |
| gptkbp:founded |
1981
|
| gptkbp:founder |
Wayne A. Marasco
|
| gptkbp:headquarters_location |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ImmunoGen
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
mirvetuximab soravtansine
|
| gptkbp:numberOfEmployees |
~300
|
| gptkbp:platform |
antibody-drug conjugate technology
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
oncology
|
| gptkbp:stockSymbol |
IMGN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.immunogen.com/
|
| gptkbp:bfsParent |
gptkb:Takeda
|
| gptkbp:bfsLayer |
6
|